Exosome-mediated cargo delivery system (EV-delivery)

Exosome-mediated cargo delivery refers to the use of small extracellular vesicles (EVs) as specialized vehicles for transporting therapeutic agents to specific cellular and extracellular sites. These vesicles, typically ranging from 30 to 150 nanometers, are naturally produced by cells to facilitate intercellular communication by carrying proteins, lipids, and various RNA species (Kalluri & LeBleu, 2020, Science). In drug development, exosomes are engineered to encapsulate diverse payloads, including small molecules, antisense oligonucleotides, and proteins, allowing them to bypass biological barriers like the blood-brain barrier (Mentkowski et al., 2018, AJP Heart Circ Physiol). This delivery platform is being explored for its potential to treat complex diseases such as cancer and neurodegenerative disorders by enabling precise targeting and reducing systemic toxicity. However, the entry 'Multiple cellular and extracellular targets via exosome-mediated cargo delivery' describes a delivery mechanism or platform rather than a single molecular target, making it an incorrect classification for a specific receptor or enzyme (NIH/NCBI, 2023).

Other names

Extracellular vesicle-mediated deliveryExosomal cargo deliveryEV-mediated transportExosome-based drug delivery platform

Facilitates the transport of therapeutic payloads (e.g., nucleic acids, proteins, small molecules) across biological membranes and barriers to reach specific intracellular or extracellular targets via endocytosis or membrane fusion (Kalluri & LeBleu, 2020, Science).